---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109146"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:24:15.702823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven

## Summary
- YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).
- Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).
- Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.
- Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
- Company achieves non-GAAP breakeven, underscoring financial discipline.

## SEC filing metadata
- accession: 0001104659-25-109146
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/0001104659-25-109146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/tm2530676d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109146
- JSON: https://secwatch.observer/filing/0001104659-25-109146.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.